



A new strategy for the treatment of viral infections - Virus like 
particles loaded with antiviral drugs for antiviral therapy and 
description of a new method to obtain genome free viruses as 
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Intact viruses, containing no viral genome but which are loaded with a therapeutic drug or virus like particles loaded 
with antiviral drugs are potentially  selective drug carriers for the intracellular delivery of therapeutics.  
These virus constructs could be used as therapeutics for the therapy of viral infections. For example HI-viruses could be 
designed, that are loaded with antisense  oligonucleotides  that  avoid replication of the wild type HI virus. The 
advantage of such antisense oligonucleotide loaded viruses could be the fact that they enter cells and deliver the 
therapeutics to the host cells of the wild type HI virus. It should be possible to treat all viral infections with this method. 
Wild type viruses are therapied by a modified virus of the same type or a virus like particle containing a antiviral drug – 
e.g. an antisense oligonucleotide. This method should work for all viruses. 
Additionally, a new method is described how intact viruses, containing no viral genome but which are loaded with a 
therapeutic drug could be obtained. The major obstacle is that the viral genome and viral proteins must be present for 
virus assembly on the one hand, on the other hand it must be removed subsequent to virus assembly in order to obtain a 
safe drug carrier. The idea is: Virus assembly takes place in the presence of the viral genome  with subsequent removal 
of the viral genome. Firstly the viral genome is immobilized on a solid support – comparable to DNA chips. Virus 
assembly proceeds at the solid support. After virus assembly and drug loading the immobilized viral genome is 
removed. Viral proteins could be obtained from a packaging cell line. The lysate of such a packaging cell line 
containing the viral proteins is incubated with the immobilized viral genome to allow virus assembly. The lysate is 
removed after succesful assembly. The next step would be the loading of the virus with a therapeutic drug. As the viral 
proteins contain amino and carboxy groups they can be chemically modified by a therapeutic drug. Finally the drug 
loaded virus is removed from the solid support and with it from the viral genome. This could be a strategy to obtain 




A virus consists of an envelope (proteins), a 
number of other functional proteins and a nucleic 
acid (DNA or RNA) [1]. Some virus types – such 
as the influenza virus – additionally contain a lipid 
layer [1].  
They specifically recognise the surface of the host 
cells. Subsequent to cell surface binding, the viral 
genome is internalized into the host cell [2]. 
Viruses can be seen as high specific carriers for 
the intracellular delivery of nucleic acids. 
Despite of their high molecular weight and their 
negative charged groups nucleic acids can not 
enter cells [3]. Gene technique utilizes viruses as 
carriers of nucleic acids into cells. The virus 
genome is modified by a non-viral polynucleotide. 
 
In order to obtain an intact virus all components it 
consists of – proteins and genome – must be 
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present during virus assembly [4, 5]. Viral 
proteins and viral genome recognise each other 
[4]. This recognition is essential for the survival 
of the specicif virus [4]. Without this specific 
recognition other nucleic acids than the one of the 
virus could be encapsidated. The nucleic acids 
must have a specific size and elelctrostatic 
interactions between the negative charged sugar-
phosphate backbone and the positive charged 
residues of the virus proteins play an important 
role in this recognition process [4, 6, 7, 8]. In 
retroviruses a specific region of the genome – the 
so called packaging signal – is responsible for 
encpasidation of the genome [10].  
By coupling ricin A to a bacteriophage RNA the 
selective delivery of ricin to host cells was 
possible [11]. However, this procedure is 
ineconomic. 
There are several reports about virus like particles. 
Capsid proteins are able to agglomerate to 
particles in the absence of the viral genome [12, 
13, 14, 15, 16]. They can be used as vaccines 
[12,13,15]. HI viruses agglomerate in the presence 
of so calles crowding agents – such as 
polyethylenglycol), however the decay of these 
virus like particels occurs quickly when the 
concentration of the crowding agents decreases 
[14].  
Virus like particles, consisting of the VP1 
(papilloma virus) are able to adsorb foreign DNA 
[17, 18]. Additionally they show affinity to sialyl 
residues being displayed on the surface of 
mammalian cells [17, 18, 19, 20]. A tissue 
specific targeting would not be possible with these 
viruses. The decay of virus like particels can be 
avoided by performing virus assembly under mild 
oxidative conditions to form disulfide bonds 
among different capsid proteins [20]. The 
incorparation of tissue specific ligans to VLPs 
would lead to tissue specificity [20]. 
The nucleocapsid of influenza viruses could can 
be removed from the lipid bilayer which contains 
cell specific lipids and viral proteins in order to 
obatin empty influenza envelope [21, 22].  
 
In this research proposal I want to present an idea 
how viruses could be obtained that are loaded 
with drugs instead of the viral genome. The major 
advantage of such viruses would be their ability 
for a selective intracellular drug delivery. 
Additionally and the major point, is that either 
genome free viruses loaded with antiviral drugs or 
tissue specific virus like particles could be used as 
specific therapeutics against viral infections 
caused by the same virus type as they should have 
the same tissue distirbution. 
Antisense oligonucleotides are drugs as well, they 
are synthetic oligoribonucleotides that are 
complementary to a specific m-RNA and they 
consists of 16-20 base pairs [23]. They are tools 
for the specific inhibition of the intracellular 
synthesis of a specific protein [23]. However, 
their intracellular bioavailability is low [24]. By 
coupling antisense oligonucleotides to carrier 
molecules they can be delivered into the cell [25, 
26]. In contrast to viruses - most carriers are not 
very specific, and some – such as somatostatine 
shows affinity only to a small number of exotic 
cell types [26].  
Whereas the utilization of viruses in gene 
technique is more or less routine – they are not 
used as specific drug carries. In order to use the 
potential of antisense oligonucleotides it would be 
a promising approach so load viruses with 
therapeutic antisense oligonucleotides instead of 
the native viral genome. Such viruses could be 
used as specific therapeutic antiviral approach 
against viruses of the same type. 
 
Antisense or drug loaded viruses as 
antiviral therapeutics 
 
Virus infections could be treated with modified 
viruses or virus like particles. Whereas the 
infectious wild type virus contains the viral 
genome, the antiviral viruses or virus like particles 
would contain antiviral drugs instead of the viral 
genome. These artifical virus constructs are 
suggested to show the same biodistribution as the 
wild type virus. 
For example HI-viruses could be designed, that 
are loaded with antisense oligonucleotides that 
avoid replication of the wild type HI virus. The 
advantage of such antisense oligonucleotide 
loaded viruses could be the fact that they enter 
cells and deliver the therapeutics to the host cells 
of the wild type HI virus. It should be possible to 
treat all viral infections with this method. Wild 
type viruses are therapied by a modified virus of 
the same type or a virus like particle containing a 
antiviral drug – e.g. an antisense oligonucleotide. 
Alternatively antisense oligonucleotides or other 
antiviral drugs (reverse transcriptase inhibito, 
proteinase inhibitors) could be adsorbed to virus 
like particels. After the infection of a cell line with 
viruses, the cells are incubated with the modified 
drug loaded viruses or the drug loaded virus like 
particles. The replication efficacy and cell 
  
3 
viability of the the cells treated with drug loaded 
viruses or virus like particels should be compared 
with control cells that were only infected. 
This strategy could lead to an improved drug 
targeting and therapy of virus infections. 
 
Hypothesis for the assembly of 
viruses loaded with drugs and 
lacking the viral genome  
 
To obtain genome free viruses (an alternative to 
virus like particels) is difficult as genome and 
proteins are necessary for virus assembly. The 
idea is to allow virus assembly in the present of 
the viral genome with subsequent removal of the 
viral genome in order to obatin a safe, non-
infectious drug. The trick is to fix the viral 
genome on a solid support – comparable to DNA 
chips – and let virus assembly take place at the 
solid support. After assembly and drug loading the 
virus is removed from the solid support. The 
immobilized viral genome could be incubated 
with a lysate form a packaging cell line. The drugs 
should be covalently coupled to the assembled 
viruses with a linker that contains a group for 
intracellular cleaavage. 
 
The idea is to immobilize the viral genome to 
allow virus assembly at the solid support. This 
makes the isolation of the viral genome easier.  
  
Immobilisation of the viral genome to a 
solid support 
 
As virus assembly is supposed to take place at a 
solid support, the viral genome must be 
immobilized. This can be realized by techniques  
used for DNA chip building. It is planed to 
covalently couple the viral genome to the solid 
support. In order to show that virus asembly 
works at the solid support the solid support loaded 
with viral genome must be incubated with the 
viral proteins which could be obtained from a 
packaging cell line. 
 
Viral proteins from a packaging cell line 
for solid phase virus  
 
A packaging cell line contains a copy of a defect 
retorviral genome [10]. All information for the 
intracellular synthesis of viral proteins are present, 
but the genome cannot be encapsidated as the 
packing signal is missing [10]. Such a cell line 
delivers all virus components necessary for virus 
assembly at the solid support.  
For this proposal only the packaging cell line 
lysate is necessary. The immobilized genome is 
incubated with the lysate. Afterwards the lysate is 
removed and the drug is covalently coupled to the 
immobilized virus.  
 
Separation fof the drug loaded viruses from the 
immobilized genome. Stability and 
functionality tests,  
 
Subsequent to drug loading of the immobilized 
viruses, the viral genome must be removed. The 
condititons must be evaluated. The separation 
could be realized under the conditions used in 
affinity chromatography by adding capsid proteins 
in a flow chamber. Furthermore the stability of the 
genome free viruses should be determined. The 
viruses could be stabilized by disulfide bond 
formation using the conditions described in 
literature 20. 
The host specifity and the intracellular delivery of 
the drug must be shown in cell culture.  
If this concept works antiviral drugs should be 
used as drugs. Paralell to this virus like particels 




 Fig 1. Solid phase virus assembly.
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